Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCC.

Fiche publication

Date publication

août 2025

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Fritzsch A, Leucht K, Röber N, Conrad K, Rothe R, Wehner R, Schumacher U, Esteban E, Barthélémy P, Schmidinger M, Schmitz M, Grimm MO

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40882246

Résumé

Immune checkpoint inhibitor (ICI) administration profoundly promotes T-cell-mediated antitumor effects, but also frequently causes the development of immune-related adverse events (irAEs) in cancer patients. Previous studies explored the relevance of autoantibodies as predictive biomarkers for irAE development and treatment response, leading to conflicting results. To gain novel insights, we determined the presence of autoantibodies and their predictive value in ICI-treated renal cell carcinoma (RCC) patients.